Regen BioPharma Inc (RGBP)

[soupoftheday]

December 2020 - Targeting the orphan nuclear receptor
NR2F6 in T cells primes tumors for immune
checkpoint therapy

As a pre-clinical
proof of concept, this establishes NR2F6 as a promising
cancer therapeutic candidate target and NR2F6 inhibition as a sensitizing concept for
next-generation
immune-oncology regimens. From a clinical perspective,
if valid, such combinatorial immunotherapy regimens including NR2F6 gene-edited ACTs are likely to
strengthen the portfolio of precision medicine applications for the successful development of personalized cancer immune therapy for improving patient survival.

https://biosignaling.biomedcentral.com/track/pdf/10.1186/s12964-019-0454-z.pdf